Is MK-677 Gyno A Myth Or Can It Really Happen?

Can MK-677 cause gyno? Not directly, as far as the evidence shows: MK-677 is not a steroid, does not act on androgen or estrogen receptors, and none of the trial safety data the FDA reviewed lists gynecomastia in men. It does raise prolactin slightly and adds body weight and water, which can make the chest look fuller. Real gyno has been reported in people taking products sold as MK-677, but in the best-documented case the products also contained hidden testosterone, estradiol and growth hormone.

Many people assume MK-677 is a SARM, but it is a growth hormone secretagogue: a drug that copies the hormone ghrelin and makes the body release more growth hormone (FDA 2024). This page goes through each way it could be linked to breast growth, what the trials found, and what to do if it happens.

Does MK-677 cause gyno?

Gynecomastia is breast tissue growth in males, usually caused by an imbalance between estrogen and testosterone (MedlinePlus). MK-677 doesn’t fit that pattern well:

• It is not a steroid. The FDA describes ibutamoren as a small molecule containing amino-acid building blocks (FDA 2024). It isn’t testosterone or a SARM, so it is not turned into estrogen.
• It did not shut down sex hormones in trials. In obese men, 8 weeks of 25 mg/day lowered total testosterone vs placebo but did not change the testosterone/SHBG ratio, LH or FSH (Svensson 1999).
• No gyno in the trial safety data. The FDA’s 2024 summary of trial side effects lists breast tenderness in one woman on MK-677 (and two on alendronate alone) in an osteoporosis trial, but no gynecomastia (FDA 2024). Men took part in several of those trials.

There are still three ways MK-677 can be linked to gyno, covered below: prolactin, growth hormone itself, and weight and water gain. A fourth, contaminated products, is the most concrete.

1. Prolactin

MK-677 raises prolactin a little. In older adults it rose 23% on 25 mg/day and stayed within the normal range (Chapman 1996); in three trials in adults over 65 it rose 27%, again within the normal range (Murphy 1999, FDA 2024). The spike is biggest after the first dose and smaller with repeated doses (Svensson 1998). Three women in the osteoporosis trial stopped because of high prolactin (FDA 2024). Very high prolactin from a pituitary tumor is a rare cause of male breast growth (MedlinePlus), but the rises seen with MK-677 were small.

2. Growth hormone itself

Gynecomastia has been reported with injected growth hormone, along with swelling, joint pain and carpal tunnel syndrome. The authors of the 12-month MK-677 trial note this as a contrast: those effects were linked to GH injections, while MK-677 raises GH in the body’s own pulses (Nass 2008). Whether MK-677 at high or long-term doses could do the same has not been studied.

3. Weight, fat and water gain

Over 12 months on 25 mg/day, body weight rose 2.7 kg vs 0.8 kg on placebo and limb fat rose more than on placebo, while mild swelling was common (Nass 2008). Fat on the chest can look like gyno; obesity is the most common cause of breast growth due to fat rather than gland tissue (MedlinePlus). A doctor can tell the difference. Read more on MK-677 water retention.

4. Products that contain more than MK-677

This is the documented route. A 40-year-old man developed breast growth on both sides and low testosterone after six months of gym supplements labeled to contain RAD-140, MK-677 and cardarine. Lab analysis found undeclared testosterone, estradiol and growth hormone in all three products. His symptoms went away after he stopped (Chong 2024). More broadly, 25% of products sold online as SARMs contained substances not on the label (Van Wagoner 2017).

Chances of MK-677 causing gyno

Nobody knows the real rate, because no study has counted it. Here is what we can say:

An older version of this page put the risk at “less than 2%” based on anecdotal reports. There is no study behind that figure, so we have removed it.

Precautions against MK-677 gyno

No study has tested ways to prevent gyno on MK-677. Based on the evidence above, the factors that matter most are:

• What is in the product. Hidden hormones are the best-documented cause. A batch-specific certificate of analysis from an independent lab is the minimum check; Sarmguide’s current partner shop is SwissChems (our review).
• What else is in the stack. SARMs can lower testosterone a lot: in one case, LGD-4033 taken with MK-677 cut total testosterone by 62% (Cardaci 2022). See our pages on RAD-140, YK-11 and ostarine gyno. The stack checker shows overlapping risks.
• What the trials measured. Investigators checked prolactin, and a few participants stopped when it rose too high (FDA 2024).

What to do if gyno happens on MK-677

• See a doctor if you have new swelling, pain or enlargement in one or both breasts, nipple discharge, or a hard lump (MedlinePlus).
• Tell them what you took. MedlinePlus advises stopping nutritional supplements and products taken for bodybuilding, and doctors may check hormone levels with blood tests (MedlinePlus). Your lab report gives its own reference ranges.
• Give it time after stopping. In the contaminated-supplement case, breast growth and low testosterone fully resolved after the man stopped (Chong 2024).

One treatment option is covered in our raloxifene for gyno guide.

Conclusion

MK-677 on its own has not been shown to cause gynecomastia: it is not a steroid, it didn’t disturb LH, FSH or free testosterone in the one trial that checked, and gyno doesn’t appear in the trial safety data. It raises prolactin slightly and adds weight and water, which can mimic gyno. The real-world cases trace back to stacks and to products containing hidden hormones. For the full safety picture, see MK-677 side effects.